

DATAR  
CANCER GENETICS

# yess...

there's a simple blood test  
to screen for multiple cancers...  
it's for your peace of mind

Multi  
Cancer

## A Simple Multi-Cancer Screening Blood Test

A Multi-Cancer Early Detection (MCED) test to screen 51 types of cancers at the same time to increase the chance of detecting cancer early.

**TriNetra**<sup>®</sup>  
Deep

## Cancer Facts

Every year about 2 million people are newly diagnosed with various cancers which cause about 610,000 deaths in the US\*. This translates into about 4 cancer cases being detected and 1 cancer related death every minute\*. Due to changes in lifestyle as well as other risk factors, these numbers are slated to increase in the future.

\*<https://seer.cancer.gov/statfacts/html/all.html>

## The Effect of Early Detection on Outcomes

### Breast

Late - Stage Survival  31%

Early - Stage Survival  99%

### Lung

Late - Stage Survival  8%

Early - Stage Survival  63%

### Colorectum

Late - Stage Survival  16%

Early - Stage Survival  91%

### Prostate

Late - Stage Survival  34%

Early - Stage Survival  100%

### Pancreas

Late - Stage Survival  3%

Early - Stage Survival  44%

### Stomach

Late - Stage Survival  7%

Early - Stage Survival  75%

### Ovary

Late - Stage Survival  30%

Early - Stage Survival  92%

#### Source

- 1.ASCO Cancer.Net.  
<https://www.cancer.net/cancer-types>.  
(10-Jun-2023)
- 2.NCI-SEER.  
<https://seer.cancer.gov/statfacts/>  
(10-Jun-2023)

## Introducing the TriNetra<sup>®</sup>-Deep test

- The TriNetra<sup>®</sup>-Deep test detects 51 types of cancers\* through a simple blood draw. The test can be availed from the comfort of your office or home.
- The TriNetra<sup>®</sup>-Deep test is indicated for individuals over the age of 50 who have an increased risk of cancer.
- The TriNetra<sup>®</sup>-Deep test should be used in addition to, and not in place of, other cancer screening tests recommended by your healthcare professional.

### TriNetra<sup>®</sup>-Deep test detects following 51 types of cancers\*:

- Adenocarcinoma (AD): Bile Duct, Breast, Colon, Duodenum, EG Junction, Esophagus, Gall Bladder, Ileum, Jejunum, Liver, Lung, Ovary, Pancreas, Prostate, Rectum, Stomach, Thyroid, Uterus, Salivary Duct; Kidney
- Adenosquamous Carcinoma: Esophagus, Gall Bladder, Lung.
- CNS Malignancies: Astrocytoma, Glioblastoma, Oligodendroglioma.
- Mesothelioma: Pleural, Peritoneal.
- Squamous Cell Carcinoma (SCC): Anorectum, Buccal Mucosa, Cervix, Esophagus, Hard Palate, Larynx, Lip, Lung, Oral Cavity, Paranasal Sinuses, Penis, Pharynx, Pyriform Fossa, Retromolar Trigone, Skin, Soft palate, Tongue, Tonsil, Vulva, Vagina.
- Transitional Cell Carcinoma (TCC): Bladder, Renal Pelvis, Ureter.



### Early Cancer Detection

Detects many cancers, such as pancreatic, ovarian, liver, esophageal, etc., that are not commonly screened for today. Early detection allows earlier treatment\*\*.



### Simple Blood Test

It can be included in a typical healthcare visit and can be availed from the comfort of your office or home.



### Functional Result

When Circulating Tumor Cells are detected, the results can indicate the location of the tumor in the body, allowing your healthcare practitioner to advise your next steps.

\* TriNetra<sup>®</sup>-Deep test is capable of detecting solid organ cancers, specifically focusing on the epithelial cancer subtype.


\*\*<https://www.cancer.gov/about-cancer/screening/screening-tests>

## The Science Behind TriNetra®-Deep

We published our ground breaking, internationally acclaimed research in 2020, where we reported the discovery of a new 'Cancer Hallmark\* i.e., Circulating Tumor Cells (CTCs) and CTC Clusters which are common in the blood of patients with carcinoma and are undetectable in completely healthy individuals.

TriNetra®-Deep is based on this technology and examines blood samples of seemingly healthy individuals for Circulating Tumor Cells (CTCs) and CTC Clusters. Detection of these in blood indicates higher risk of presence of an underlying carcinoma at the time of testing.

*\*Ranade et al, Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer Prev Res (Phila) 1 January 2021; 14 (1): 11–16. <https://doi.org/10.1158/1940-6207.CAPR-20-0322>*



## TriNetra<sup>®</sup>-Deep is Clinically Validated

TriNetra<sup>®</sup>-Deep has been clinically validated by one of the world's largest clinical trials. The validation in a large cohort clinical study is based on samples from more than 34,000 known cancer patients and more than 23,000 healthy individuals.



### International Journal of Cancer – IJC

<https://doi.org/10.1002/ijc.32815>

---

Circulating Ensembles of Tumor Associated Cells: A Redoubtable New Systemic Hallmark of Cancer.



### American Association for Cancer Research – AACR

<https://doi.org/10.1158/1940-6207.CAPR-20-0322>

---

Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk.



### ACS Journals – Cancer Cytopathology

<https://doi.org/10.1002/cncy.22366>

---

Evaluation of Circulating Tumor Cell Clusters for Pan-Cancer Noninvasive Diagnostic Triaging.



### Cancers

<https://doi.org/10.3390/cancers14143341>

---

Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells.



### Cancer Medicine

<https://doi.org/10.1002/cam4.5649>

---

Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells.



# yes...

The request for a test  
begins with you...

it's for your peace of mind

## Request

### The Test

TriNetra®-Deep test may be ordered by a licensed medical practitioner or on our website ([trinetra360.com](http://trinetra360.com)).

## Test

### Begins

Fix an appointment for collection of blood sample by our trained technician at a location of your choice.

## Results

The test result will be available upto 12 days from receipt of sample.

## Important Information

Please note that the results of this test are not to be used as the sole means of diagnosis and are not intended to substitute standard-of-care procedures. A licensed medical practitioner should interpret results. Please also be mindful of the limitations of the test, which include the possibilities of 'false positives' and 'false negatives' for the detection of CTCs due to biological variations beyond the performance spectrum of the test. In case of any questions, please get in touch with [response.us@datarpgx.com](mailto:response.us@datarpgx.com).

### Important

This test is not conducted on pregnant women.

## Frequently Asked Questions

### 1. What is the turnaround time of the test?

- ✓ The test result will be communicated within 12 days of sample receipt at the US Laboratory.

### 2. How often can the TriNetra-Deep test be performed?

- ✓ TriNetra<sup>®</sup>-Deep can be performed annually as a screening test.

### 3. What will the report tell me?

- ✓ The report will tell you if CTCs were detected (indicating higher risk of presence of cancer) or CTCs were not detected (indicating a lower risk of presence of cancer) in the submitted sample. When Circulating Tumor Cells are detected, the results can indicate the location of the tumor in the body, allowing your healthcare practitioner to advise your next steps.

### 4. What are the next steps for those with higher risk of presence of cancer?

- ✓ Individuals with these findings are advised consultation with their physician for appropriate guidance and additional standard of care work up as may be advised.

### 5. What are the next steps for those with a lower risk of presence of cancer?

- ✓ TriNetra<sup>®</sup>-Deep test may be repeated annually and the individual is advised to consult a physician if further guidance is required.

### 6. Is this a genetic predisposition test?

- ✓ No. This test detects presence of intact Circulating Tumor Cells (CTCs) in peripheral blood of the individual.

### 7. Does TriNetra<sup>®</sup>-Deep replace conventional cancer screening like colonoscopy and mammography?

- ✓ TriNetra<sup>®</sup>-Deep is not intended to be and should not be considered as a replacement for any Standard of Care screening tests.

### 8. What are CTCs?

- ✓ These are the tumor cells which are circulating in blood when shed from the carcinoma.

# DATAR CANCER GENETICS

## Essential Safety Information

The TriNetra®-Deep test is advised for use in adults with a higher risk of developing cancer, typically those who are above 50 years of age. The TriNetra®-Deep test should be used in addition to other cancer screening procedures advised by a healthcare professional, as TriNetra®-Deep may not always detect all cancers. The objective of using TriNetra®-Deep is to identify cancer footprints i.e. CTCs and identify the probable organ / location that may be affected. TriNetra®-Deep should not be used by anyone who is pregnant, under the age of 50, or receiving active cancer treatment. TriNetra®-Deep should never be used as the sole means of diagnosis and the results must always be corroborated by Standard of Care methodologies undertaken through a duly qualified and authorized medical professional.

A healthcare professional should interpret the results in light of the patient's medical history, physical symptoms, and clinical indicators. A "No Circulating Tumor Cells Detected" test result merely signifies a reduced risk of detecting cancer but it however does not definitively exclude the possibility of cancer. A "Circulating Tumor Cells Detected" test result must necessarily be confirmed by independent diagnostic evaluation using medically accepted Standard of Care techniques (like imaging, for example) and a positive result does not imply the existence of cancer.

If additional testing does not confirm the presence of cancer, it may indicate that cancer is not currently present (the TriNetra®-Deep test is 'false-positive'), and 'watchful waiting' is advised subject to the opinion of the individual's prescribing physician. It is clarified that owing to the diverse biological behavior of cancer and/or the technical limitations of the performance of the test, it is possible for the test findings to be both false-positive (a biological footprint suggestive of cancer is found when cancer is not present) and false-negative (a biological footprint suggestive of cancer is not identified when cancer is present). Prescription Required.


## Information from the laboratory about the test

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford, UK, and the College of American Pathologists (CAP) has granted it accreditation. The TriNetra®-Deep test was developed by Datar Cancer Genetics, and the Company has determined the performance parameters of the test. The Food and Drug Administration (US-FDA) has neither approved, endorsed, nor cleared the TriNetra®-Deep test. High-complexity testing is regulated under the CLIA regime in the Company's clinical laboratory. The TriNetra®-Deep test is designed to be used in a clinical setting only.

---

## Contact us:

**US:** [response.us@datarpgx.com](mailto:response.us@datarpgx.com)

 [trinetra360.com](https://trinetra360.com)

Proprietary Technology, All Intellectual Property Rights Protected under relevant laws.

© 2023, Datar Cancer Genetics. All rights reserved. TriNetra is a registered trademark of Datar Cancer Genetics